Research peptides in Canada: prescription drugs by definition, and no exemption for the label

Canada has the most active enforcement record on research peptides of any country in this series, and the shortest legal argument. The Food and Drugs Act defines a drug by what a substance is sold or represented for. Health Canada's position, stated in December 2023 and repeated since, is that most peptides sold in vials are prescription drugs, that an unauthorized drug is illegal to sell, and that a label reading "For Research Use Only – Not for Human Consumption" changes none of that. Between December 2023 and June 2026 the department ordered one online seller to stop, seized products from three others, named fifty-odd peptides in public advisories, and obtained a permanent injunction from the Superior Court of Québec. This page sets out the statute and regulations, how the department reads them, what it has done, what happens at the border, and where research material stands.

The statute: a drug is what it is represented for

Section 2 of the Food and Drugs Act defines a drug as any substance or mixture of substances manufactured, sold or represented for use in the diagnosis or mitigation of disease in people or animals, or in restoring, correcting or modifying organic functions in human beings or animals. The definition does not list molecules. It asks what the substance is manufactured, sold or represented for, and a peptide sold with a claim about the body is a drug on the day the claim is made. Section 9(1) adds that no person may label, package, treat, process, sell or advertise any drug in a manner that is false, misleading or deceptive or is likely to create an erroneous impression regarding its character, value, quantity, composition, merit or safety, which is the provision that reaches a research label on a product sold for use.

Two regulations then do the work. Regulation C.01.014(1) of the Food and Drug Regulations: No manufacturer shall sell a drug in dosage form unless a drug identification number has been assigned for that drug. The eight-digit DIN on a label is the mark of an authorized drug, and Health Canada tells the public to look for it. Regulation C.01.041(1): No person shall sell a prescription drug unless they are entitled under provincial law to dispense it and sell it on a prescription. Which drugs are prescription drugs is set by the Prescription Drug List that the Minister keeps under section 29.1 of the Act; a list, the Act says, that is not a regulation, so it can be amended without one. Penalties under section 31 are modest on paper, a fine and up to three years on indictment, which is why the department's instruments are seizure, border refusal and injunction rather than prosecution.

How Health Canada reads it for peptides

The department's position was set out in a public advisory of December 13, 2023 ordering an online seller of peptides marketed for research to stop: Most synthetic injectable peptides are regulated as prescription drugs in Canada and require a prescription from a licenced health care professional. It has not moved since. The advisory of April 9, 2026 restates it as peptides are generally regulated as prescription drugs, and the department's statement on the June 2026 injunction puts it without qualification: In Canada, injectable peptides are regulated as prescription drugs and must be authorized by Health Canada before they can be sold.

On the research label the department is equally direct. The April 2026 advisory: Health Canada continues to identify products marketed as 'For Research Use Only – Not for Human Consumption.' This type of labelling does not make these products legal or exempt from regulatory requirements. A law firm's review of the position in September 2026 described the method as the department evaluating the totality of a product's presentation and marketing, including websites, product descriptions, claims, advertising and the context in which it is being offered. That is the American intended-use inquiry under a different name, applied to a definition that already turns on representation.

Three things follow for a research peptide in Canada. A peptide in a vial, presented in any way for use in the body, is a prescription drug. A prescription drug without a DIN may not be sold at all, by anyone, prescription or not. And a research label on such a product is at best irrelevant and at worst a misleading representation under section 9.

The record, December 2023 to June 2026

• December 13, 2023. Health Canada orders an online seller of peptides marketed for research to stop advertising and selling all unauthorized health products, naming oxytocin and triptorelin among them, and warns of further action. This is the first Canadian action against a research-labeled peptide seller as such.
• June 26, 2024. The department seizes products from a company operating two websites that sold peptides for bodybuilding, anti-ageing and athletic performance alongside nootropics and a selective androgen receptor modulator, and has the sites taken down.
• April 14, 2025. Seizure of peptide products from a second online seller, with BPC-157, PT-141 and TB-500 pictured in the advisory: Health Canada has not authorized any of the products sold on [the seller's] website, which means they have not been assessed for safety, efficacy and quality and it is illegal to sell them in Canada.
• August 1, 2025. Seizure from a third online seller, with a public list of thirty-eight peptides, among them BPC-157, CJC-1295, ipamorelin, TB-500, GHK, DSIP, epitalon, semax, selank, sermorelin, tesamorelin, thymosin alpha-1 and thymosin beta-4. The advisory's one-line statement of the law: Selling unauthorized drugs is illegal in Canada.
• April 9, 2026. The general advisory, Think twice before injecting peptides bought online, naming fourteen peptides seized or sold online, stating that the department is working with the Canada Border Services Agency to stop unauthorized shipments from entering the country, and rejecting research labeling in terms. Health Canada told the press it had received four complaints of adverse reactions in six months in which unauthorized peptides were suspected.
• June 11, 2026. The Superior Court of Québec grants Health Canada a permanent injunction against the seller it had ordered to stop in December 2023, which had, in the department's words, continued selling unauthorized peptide drugs on various websites and promoting them with many unproven health claims, despite repeated enforcement actions. The order bars the company from manufacturing, testing, distributing, selling or advertising unauthorized peptides, on any website or social media platform accessible from a Canadian address. Announced July 29, 2026.

The sequence is instructive. Each seller was first asked to stop. Each advisory named the products and reproduced the labels. The one seller that did not stop was taken to court, and the court gave the department everything it asked for. The injunction is the first of its kind in this series and the model for what a persistent research-labeled seller can expect in Canada.

The border

Health Canada's compliance and enforcement policy lists, among its tools, recommending the refusal or seizure of imports at the border and ordering the removal or destruction of imports at the border, and the April 2026 advisory confirms the Canada Border Services Agency is applying them to peptides. The personal-use rules close the obvious route. Under the department's guidance on bringing health products into Canada, a Canadian resident is generally not allowed to bring prescription drugs into Canada by mail or courier; the exceptions are for drugs prescribed in Canada or continuing a course begun abroad, and a resident returning in person may carry only what was prescribed and filled in Canada. A peptide the department regards as a prescription drug, arriving by post without a DIN, meets none of those conditions. The department may refuse it entry, seize it or order it destroyed.

Commercial import is a different matter. A drug may be imported for sale only by the holder of an establishment licence, and a research chemical may be imported as a chemical. The question at the border is which of those a parcel of peptide vials is, and the department has told the Border Services Agency how it answers that for products presented for use in the body.

Where research material stands

Everything above concerns peptides sold or represented for use in people. The statute's definition is triggered by representation, and the department's method reads representation from the whole presentation. A peptide sold to a laboratory as a characterized chemical, with no representation for use in the body, no format implying it, and documentation of what it is, is not within the section 2 definition on its face. Canada has no equivalent of Australia's scheduling, which would make the molecule itself controlled. Nor has Health Canada published any action against a laboratory or against a supplier of research material that made no representation.

What the record shows is where the line is drawn in practice. Every seller acted against sold in single-use vials, promoted effects, priced by the course or marketed to the fitness and anti-ageing trade, and the department's advisories reproduce those presentations as the evidence. The research label was on several of them. It did not help, because the department does not read the label in isolation, and the Act does not ask it to. A supplier of research peptides to Canadian laboratories is in the position the pillar of this series describes for every jurisdiction: the label describes intent, the rest of the presentation has to agree with it, and the department will read all of it.

What is different, and what is the same

• The definition is representation, not intent or presentation-and-function. The result is the same evidence read the same way, but Canada's test is the simplest of the five: sold or represented for use in modifying a body function is enough.
• The DIN rule bites before the prescription rule. A peptide without a DIN cannot be sold by anyone. The prescription question never has to be reached.
• Enforcement is by seizure, publication and injunction. Four public advisories that name products and reproduce labels, three seizures, one court order. No prosecution, and no action against buyers.
• The research label is rejected in writing. Canada is the only one of the five whose regulator has published a sentence saying the label does not exempt a product. The others say it by inference.

What to watch

• Whether the department seeks a second injunction, which would show the June 2026 order is a template rather than a one-off.
• Any amendment to the Prescription Drug List adding peptide classes by name, which the Minister can do without a regulation.
• Border figures. The department has said it is working with the Border Services Agency but has published no counts of peptide shipments refused or seized.
• Whether the four adverse-reaction complaints reported in April 2026 grow into the kind of record that drove Australia's scheduling.

Frequently asked questions

Are research peptides legal in Canada?

A peptide sold or represented for use in the body is a drug under section 2 of the Food and Drugs Act, and Health Canada regards most peptides sold in vials as prescription drugs. Without a DIN it is illegal to sell. A research label does not exempt it, in the department's published words. Material sold to a laboratory with no representation for use in the body is outside the definition on its face, and no action against such a supplier is on the record.

Is BPC-157 legal in Canada?

No BPC-157 product holds a DIN, so none may be sold. Health Canada has named it in seizures and advisories in 2025 and 2026. Its actions have been against sellers, not buyers.

Can I import peptides into Canada for personal use?

Health Canada's guidance says a resident is generally not allowed to bring prescription drugs into Canada by mail or courier, and the department is working with the Border Services Agency to stop unauthorized peptide shipments. Non-compliant shipments may be refused, seized or destroyed. This page describes the rules and does not advise anyone to import anything.

Does "For Research Use Only – Not for Human Consumption" mean anything in Canada?

Health Canada's April 2026 advisory says this labeling "does not make these products legal or exempt from regulatory requirements". The department reads the whole presentation, and every seller it has acted against presented its products for use in the body.

Who enforces peptide law in Canada?

Health Canada, through public advisories, stop orders, seizures and court injunctions; the Canada Border Services Agency at the border on Health Canada's recommendation; and the Public Prosecution Service of Canada if a case is referred for prosecution, which none has been.

Sources & Further Reading

1. Food and Drugs Act, R.S.C. 1985, c. F-27: section 2 (definition of "drug"), section 9(1) (deception), section 29.1 (prescription drug list), section 31 (offences and punishment).
2. Food and Drug Regulations, C.R.C., c. 870: C.01.014(1) (drug identification number), C.01.041(1) (sale of prescription drugs).
3. Health Canada, Prescription Drug List; Health Canada, Compliance and enforcement policy for health products (POL-0001); Health Canada, Bringing health products into Canada for personal use (GUI-0116), July 13, 2026.
4. Health Canada public advisories: unauthorized peptides sold by an online seller marketed for research, December 13, 2023; unauthorized drug products sold on two websites, June 26, 2024 (updated July 19, 2024); unauthorized peptide products seized from an online seller, April 14, 2025; unauthorized peptide products seized from an online seller, August 1, 2025, listing thirty-eight peptides; Think twice before injecting peptides bought online: unauthorized products can seriously harm you, April 9, 2026. Sellers' names are omitted here by this library's policy; each advisory names them.
5. Health Canada news release, permanent injunction granted by the Superior Court of Québec on June 11, 2026, announced July 29, 2026; Global News, July 29, 2026.
6. CP24/CTV News, April 17, 2026, reporting Health Canada's statement and the four adverse-reaction complaints; The Conversation, May 6, 2026 (Stuart Phillips, McMaster University).
7. Gowling WLG, "Peptides in Canada: regulatory reality is catching up with the hype", September 9, 2026.

Cosmic Peptides. (2026, November 1). Research peptides in Canada: prescription drugs by definition, and no exemption for the label. Cosmic Peptides Research Library. Retrieved November 2, 2026, from https://cosmicpeptides.com/research/compliance/research-peptides-in-canada

@misc{cosmicpeptides_research_compliance_research_peptides_in_canada,
  author       = {{Cosmic Peptides}},
  title        = {Research peptides in Canada: prescription drugs by definition, and no exemption for the label},
  howpublished = {Cosmic Peptides Research Library},
  year         = {2026},
  month        = nov,
  url          = {https://cosmicpeptides.com/research/compliance/research-peptides-in-canada},
  urldate      = {2026-11-02},
  note         = {Last reviewed 2026-11-01}
}

TY  - ELEC
AU  - Cosmic Peptides
TI  - Research peptides in Canada: prescription drugs by definition, and no exemption for the label
T2  - Cosmic Peptides Research Library
PB  - Cosmic Peptides
PY  - 2026
DA  - 2026/11/01
UR  - https://cosmicpeptides.com/research/compliance/research-peptides-in-canada
Y2  - 2026/11/02
LA  - en
ER  -